[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...
.

Atrasentin, an Endothelin A (et-a) receptor antagonist, may inhibit prostate cancer metastases in bone

Osteoblastic (white on x-ray) bone metastases are characteristic of prostate cancer. Endothelin-1 (ET-1) plays a key role in bone-tumour interactions, producing the osteoblastic phenotype (via G-protein/ET-A receptor interactions). Atrasentin, a potent ET-A receptor antagonist - that is now orally active and available in pill form - appears to be active in the inhibition of prostate cancer progression in bone, after these patients have failed orthodox hormonal therapies. This information was reported at the influential American Society of Clinical Oncology meeting (San Francisco, May 2001) by clinical researchers in collaboration with Abbott laboratories.